Refine
Has Fulltext
- yes (2)
Is part of the Bibliography
- yes (2)
Document Type
- Journal article (1)
- Doctoral Thesis (1)
Language
- English (2)
Keywords
- Staphylococcus aureus (2)
- Enoyl-Reduktase (1)
- Enoyl-acyl-carrier-protein-Reductase (1)
- Fettsäurebiosynthese (1)
- Fettsäurestoffwechsel (1)
- Inhibition (1)
- Kristallstruktur (1)
- Lipide (1)
- LpxC inhibitors (1)
- Wirkstoff (1)
- antibacterial activity (1)
- enoyl reductase (1)
- enoyl-ACP reductase inhibitors (1)
- fatty acid biosynthesis (1)
Drug-target kinetics enable time-dependent changes in target engagement to be quantified as a function of drug concentration. When coupled to drug pharmacokinetics (PK), drug-target kinetics can thus be used to predict in vivo pharmacodynamics (PD). Previously we described a mechanistic PK/PD model that successfully predicted the antibacterial activity of an LpxC inhibitor in a model of Pseudomonas aeruginosa infection. In the present work we demonstrate that the same approach can be used to predict the in vivo activity of an enoyl-ACP reductase (FabI) inhibitor in a model of methicillin-resistant Staphylococcus aureus (MRSA) infection. This is significant because the LpxC inhibitors are cidal, whereas the FabI inhibitors are static. In addition P. aeruginosa is a Gram-negative organism whereas MRSA is Gram-positive. Thus this study supports the general applicability of our modeling approach across antibacterial space.